Vanin 1 (<i>VNN1</i>) levels predict poor outcome in acute myeloid leukemia

Izzi, Valerio; Lakkala, Juho; Devarajan, Raman; Savolainen, Eeva‐Riitta; Koistinen, Pirjo; Heljasvaara, Ritva; Pihlajaniemi, Taina

doi:10.1002/ajh.24925

Cited by 10 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a VNN1 gene was proposed for improving therapy outcomes and as relapse risk biomarker. Higher expression of VNN1 was associated with poor outcomes, including resistance to chemotherapy and shorter relapse periods [114].…”

Section: Cancersmentioning

confidence: 99%

The Pathophysiological Role of CoA

Czumaj

Szrok-Jurga

Hebanowska

et al. 2020

IJMS

View full text Add to dashboard Cite

The importance of coenzyme A (CoA) as a carrier of acyl residues in cell metabolism is well understood. Coenzyme A participates in more than 100 different catabolic and anabolic reactions, including those involved in the metabolism of lipids, carbohydrates, proteins, ethanol, bile acids, and xenobiotics. However, much less is known about the importance of the concentration of this cofactor in various cell compartments and the role of altered CoA concentration in various pathologies. Despite continuous research on these issues, the molecular mechanisms in the regulation of the intracellular level of CoA under pathological conditions are still not well understood. This review summarizes the current knowledge of (a) CoA subcellular concentrations; (b) the roles of CoA synthesis and degradation processes; and (c) protein modification by reversible CoA binding to proteins (CoAlation). Particular attention is paid to (a) the roles of changes in the level of CoA under pathological conditions, such as in neurodegenerative diseases, cancer, myopathies, and infectious diseases; and (b) the beneficial effect of CoA and pantethine (which like CoA is finally converted to Pan and cysteamine), used at pharmacological doses for the treatment of hyperlipidemia.

show abstract

Section: Cancersmentioning

confidence: 99%

The Pathophysiological Role of CoA

Czumaj

Szrok-Jurga

Hebanowska

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In previous studies, VNN1 mRNA had been used to predict the risk or prognosis of colorectal cancer (18,19) and acute myeloid leukemia patients (20). Elevated circulation or urinary vanin-1 has been reported in acute/chronic kidney injury (21,22), drug-induced renal injury (23) and asthma patients (24).…”

Section: Discussionmentioning

confidence: 99%

Plasma vanin-1 as a novel biomarker of sepsis for trauma patients: a prospective multicenter cohort study

Lu¹,

Zhang²,

Wen³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroudVanin-1 plays a pivotal role in oxidative stress and the inflammatory response. However, its relationship with traumatic sepsis remains unknown. The aim of our study was to evaluate whether plasma vanin-1 expression can be used to predict traumatic sepsis in an early time.MethodsIn this three-stage prospective cohort study, severe trauma patients admitted to two hospitals from January 2015 to October 2018 were enrolled. Clinical data during hospitalization and APACHE II score were collected. Plasma vanin-1 levels were measured by enzyme linked immunosorbent assay. The associations among variables and traumatic sepsis were identified by logistic regression model. The receiver-operating characteristic curve was analyzed to evaluate the diagnostic efficiency of the selected factors.ResultsA total of 426 trauma patients (22 patients in the discovery cohort, 283 patients in the internal test cohort, and 121 patients in the external validation cohort) and 16 healthy volunteers were enrolled. The plasma vanin-1 level of trauma patients was significantly higher than that of healthy volunteers (P < 0.05), and sepsis patients had higher plasma vanin-1 than non-sepsis patients in the discovery trauma cohort (P < 0.05). In the internal test cohort, plasma vanin-1 levels at day 1 after trauma were significantly associated with the incidence of sepsis (OR = 3.92, 95% CI = 2.68–5.72, P = 1.62⊆10− 12). As a predictive biomarker, vanin-1 obtained a better area under the curve (AUC) (0.82, 95% CI = 0.77–0.87) than C-reaction protein (CRP) (0.62, 95% CI = 0.56–0.68, P < 0.0001), procalciton in (PCT) (0.66, 95% CI = 0.60–0.71, P < 0.0001), and Acute Physiology and Chronic Health Evaluation II (APACHE II) (0.71, 95% CI = 0.65–0.76, P = 6.70⊆10− 3). In addition, the clinical relevance between plasma vanin-1 and traumatic sepsis was validated in the external validation cohort (OR = 4.26, 95% CI = 2.22–8.17, P = 1.28⊆10− 5). The AUC of vanin-1 was 0.83 (95% CI = 0.75–0.89), which was better than that of CRP, PCT, and APACHE II.ConclusionsOur study demonstrated that plasma vanin-1 increased among trauma patients and was independently associated with the risk of sepsis. Vanin-1 might be a potential biomarker for the early prediction of traumatic sepsis.Trial registrationClinicaltrials.gov Identifier NCT01713205. Registered 24 October 2012.

show abstract